XINROI PHARMACEUTICALS INTERNATIONAL HOLDINGS LIMITED (XINYUI PHARMACEUTICALS) ANNOUNCED ON 28 MAY 2024 THAT ITS WHOLLY OWNED SUBSIDIARIES CHINA XINROI HAVE SIGNED A CORNERSTONE INVESTMENT AGREEMENT WITH JIANGXI SUNSHINE GROUP, CITIC SECURITIES (HONG KONG) LIMITED AND CITIC LION SECURITIES LIMITED. Under the agreement, New China will subscribe for investor shares in Jiangxi Sunshine Group for HKD12,000,000, excluding brokerage commissions and fees to be paid. The cornerstone investment constitutes a disclosable transaction in accordance with the listing rules because it involves a maximum percentage of more than 5% but less than 25%. Jiangxi Yinghua Sunshine Group, a medical group specializing in medical imaging services, believes that this investment is in line with the company's diversified development strategy and will help bring long-term return on investment...Show More

XINROI PHARMACEUTICALS INTERNATIONAL HOLDINGS LIMITED (XINYUI PHARMACEUTICALS) ANNOUNCED ON 28 MAY 2024 THAT ITS WHOLLY OWNED SUBSIDIARIES CHINA XINROI HAVE SIGNED A CORNERSTONE INVESTMENT AGREEMENT WITH JIANGXI SUNSHINE GROUP, CITIC SECURITIES (HONG KONG) LIMITED AND CITIC LION SECURITIES LIMITED. Under the agreement, New China will subscribe for investor shares in Jiangxi Sunshine Group for HKD12,000,000, excluding brokerage commissions and fees to be paid. The cornerstone investment constitutes a disclosable transaction in accordance with the listing rules because it involves a maximum percentage of more than 5% but less than 25%. Jiangxi Yinghua Sunshine Group, a medical group specializing in medical imaging services, believes that this investment is in line with the company's diversified development strategy and will help bring long-term return on investment for shareholders. Investment completion is subject to certain prerequisites, including relevant approvals, permits or exemptions, and acceptance by the China Securities and Exchange Commission, etc. If the conditions are not met, the cornerstone investment agreement will be terminated. Novi Pharmaceuticals also agrees not to sell any investor shares purchased under the agreement for a period of twelve months from the listing date.